XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

XenTech remains fully operational after 7 weeks of COVID-19 pandemic : update from our COO

Dear valued customers   In this 7th week of containment and as end of confinement in France is announced for May 11th, I would first of all like to thank you on behalf of our teams for all the messages of support you have sent us since the beginning of the COVID-19 crisis.   From […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...